Die Bedeutung der Lebensqualität bei Rheumatoider Arthritis (RA)

Publikation: Beitrag in FachzeitschriftÜbersichtsarbeitForschungPeer-Review

Autorschaft

  • T. Mittendorf
  • W. Greiner
  • J. M. Von Graf Der Schulenburg

Organisationseinheiten

Forschungs-netzwerk anzeigen

Details

Titel in ÜbersetzungThe Meaning of Quality of Life with Rheumatoid Arthritis (RA)
OriginalspracheMehrere Sprachen
Seiten (von - bis)322-328
Seitenumfang7
FachzeitschriftGesundheitsokonomie und Qualitatsmanagement
Jahrgang9
Ausgabenummer5
Frühes Online-Datum27 Sept. 2004
PublikationsstatusVeröffentlicht - Okt. 2004

Abstract

In recent years a number of novel substances have been introduced in the treatment of Rheumatoid Arthritis (RA). In the group of pain relieve drugs the group of coxib's should be mentioned above all, whom are believed in having a better risk profile with complications in the gastrointestinal area. The TNF-α antagonist's ethanercept, adalimumab and infliximab were added to the disease modifying drugs (DMARDs), which are designed to slow or stop a progression of RA. These new active substances are far more costly than comparators already in the market, which may be justified by a superior outcome, which is subject of a number of health economic evaluation studies to date. Those health-economic evaluations often try to model advantages of those novel substances in order to show the long-term effects on direct and indirect cost domains. The long term data needed for a high validity of the models is very limited. Therefore it is very important for medical groups in the field of RA, to learn more about certain aspects of the health related quality of life accompanied with different treatment regimens as a special field in health economics. Hence, we give the reader the methodical tools, so that results of quality of life studies in RA may be added and enrich the structure of health services given to patients in daily practice.

Schlagwörter

    Ambulatory care, Quality of life, Rheumatoid arthritis

ASJC Scopus Sachgebiete

Ziele für nachhaltige Entwicklung

Zitieren

Die Bedeutung der Lebensqualität bei Rheumatoider Arthritis (RA). / Mittendorf, T.; Greiner, W.; Von Graf Der Schulenburg, J. M.
in: Gesundheitsokonomie und Qualitatsmanagement, Jahrgang 9, Nr. 5, 10.2004, S. 322-328.

Publikation: Beitrag in FachzeitschriftÜbersichtsarbeitForschungPeer-Review

Mittendorf, T, Greiner, W & Von Graf Der Schulenburg, JM 2004, 'Die Bedeutung der Lebensqualität bei Rheumatoider Arthritis (RA)', Gesundheitsokonomie und Qualitatsmanagement, Jg. 9, Nr. 5, S. 322-328. https://doi.org/10.1055/s-2004-813648
Mittendorf, T., Greiner, W., & Von Graf Der Schulenburg, J. M. (2004). Die Bedeutung der Lebensqualität bei Rheumatoider Arthritis (RA). Gesundheitsokonomie und Qualitatsmanagement, 9(5), 322-328. https://doi.org/10.1055/s-2004-813648
Mittendorf T, Greiner W, Von Graf Der Schulenburg JM. Die Bedeutung der Lebensqualität bei Rheumatoider Arthritis (RA). Gesundheitsokonomie und Qualitatsmanagement. 2004 Okt;9(5):322-328. Epub 2004 Sep 27. doi: 10.1055/s-2004-813648
Mittendorf, T. ; Greiner, W. ; Von Graf Der Schulenburg, J. M. / Die Bedeutung der Lebensqualität bei Rheumatoider Arthritis (RA). in: Gesundheitsokonomie und Qualitatsmanagement. 2004 ; Jahrgang 9, Nr. 5. S. 322-328.
Download
@article{f81411ca84234cfea9aba2f5c0800630,
title = "Die Bedeutung der Lebensqualit{\"a}t bei Rheumatoider Arthritis (RA)",
abstract = "In recent years a number of novel substances have been introduced in the treatment of Rheumatoid Arthritis (RA). In the group of pain relieve drugs the group of coxib's should be mentioned above all, whom are believed in having a better risk profile with complications in the gastrointestinal area. The TNF-α antagonist's ethanercept, adalimumab and infliximab were added to the disease modifying drugs (DMARDs), which are designed to slow or stop a progression of RA. These new active substances are far more costly than comparators already in the market, which may be justified by a superior outcome, which is subject of a number of health economic evaluation studies to date. Those health-economic evaluations often try to model advantages of those novel substances in order to show the long-term effects on direct and indirect cost domains. The long term data needed for a high validity of the models is very limited. Therefore it is very important for medical groups in the field of RA, to learn more about certain aspects of the health related quality of life accompanied with different treatment regimens as a special field in health economics. Hence, we give the reader the methodical tools, so that results of quality of life studies in RA may be added and enrich the structure of health services given to patients in daily practice.",
keywords = "Ambulatory care, Quality of life, Rheumatoid arthritis",
author = "T. Mittendorf and W. Greiner and {Von Graf Der Schulenburg}, {J. M.}",
year = "2004",
month = oct,
doi = "10.1055/s-2004-813648",
language = "Multiple languages",
volume = "9",
pages = "322--328",
number = "5",

}

Download

TY - JOUR

T1 - Die Bedeutung der Lebensqualität bei Rheumatoider Arthritis (RA)

AU - Mittendorf, T.

AU - Greiner, W.

AU - Von Graf Der Schulenburg, J. M.

PY - 2004/10

Y1 - 2004/10

N2 - In recent years a number of novel substances have been introduced in the treatment of Rheumatoid Arthritis (RA). In the group of pain relieve drugs the group of coxib's should be mentioned above all, whom are believed in having a better risk profile with complications in the gastrointestinal area. The TNF-α antagonist's ethanercept, adalimumab and infliximab were added to the disease modifying drugs (DMARDs), which are designed to slow or stop a progression of RA. These new active substances are far more costly than comparators already in the market, which may be justified by a superior outcome, which is subject of a number of health economic evaluation studies to date. Those health-economic evaluations often try to model advantages of those novel substances in order to show the long-term effects on direct and indirect cost domains. The long term data needed for a high validity of the models is very limited. Therefore it is very important for medical groups in the field of RA, to learn more about certain aspects of the health related quality of life accompanied with different treatment regimens as a special field in health economics. Hence, we give the reader the methodical tools, so that results of quality of life studies in RA may be added and enrich the structure of health services given to patients in daily practice.

AB - In recent years a number of novel substances have been introduced in the treatment of Rheumatoid Arthritis (RA). In the group of pain relieve drugs the group of coxib's should be mentioned above all, whom are believed in having a better risk profile with complications in the gastrointestinal area. The TNF-α antagonist's ethanercept, adalimumab and infliximab were added to the disease modifying drugs (DMARDs), which are designed to slow or stop a progression of RA. These new active substances are far more costly than comparators already in the market, which may be justified by a superior outcome, which is subject of a number of health economic evaluation studies to date. Those health-economic evaluations often try to model advantages of those novel substances in order to show the long-term effects on direct and indirect cost domains. The long term data needed for a high validity of the models is very limited. Therefore it is very important for medical groups in the field of RA, to learn more about certain aspects of the health related quality of life accompanied with different treatment regimens as a special field in health economics. Hence, we give the reader the methodical tools, so that results of quality of life studies in RA may be added and enrich the structure of health services given to patients in daily practice.

KW - Ambulatory care

KW - Quality of life

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=6044270363&partnerID=8YFLogxK

U2 - 10.1055/s-2004-813648

DO - 10.1055/s-2004-813648

M3 - Review article

AN - SCOPUS:6044270363

VL - 9

SP - 322

EP - 328

JO - Gesundheitsokonomie und Qualitatsmanagement

JF - Gesundheitsokonomie und Qualitatsmanagement

SN - 1432-2625

IS - 5

ER -